1,788
Views
3
CrossRef citations to date
0
Altmetric
Respiratory Medicine

A budget impact analysis of budesonide/formoterol in patients with mild asthma in Egypt

ORCID Icon, , , , , & show all
Pages 1047-1054 | Received 18 May 2019, Accepted 07 Jul 2019, Published online: 01 Aug 2019

References

  • Wisnivesky J, Leventhal H, Halm E. Predictors of asthma-related healthcare utilization and quality of life among inner-city patients with asthma. J Allergy Clin Immunol. 2005;116:636–642.
  • The Global Asthma Report 2014. In.: Global Asthma Network; 2014 [cited 2019 Apr 10]. Available from: www.globalasthmanetwork.org/publications/Global_Asthma_Report_2014.pdf.
  • Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. In.: World Health Organisation; 2007 [cited 2019 Apr 1]. Available from: https://www.who.int/gard/publications/GARD_Manual/en/.
  • Stanojevic TS, Moores G, Gershon AS, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.
  • Alsowaidi S, Abdulle A, Bernsen R, et al. Allergic rhinitis and asthma: a large cross-sectional study in the United Arab Emirates. Int Arch Allergy Immunol. 2010;153:274–279.
  • Mahboub BH, Al-Hammadi S, Rafique M, et al. Population prevalence of asthma and its determinants based on European Community respiratory health survey in the United Arab Emirates. BMC Pulm Med. 2012;12:4.
  • Adeloye D, Chan KY, Rudan I, et al. An estimate of asthma prevalence in Africa: a systematic analysis. Croat Med J. 2013;54:519–531.
  • Tarraf H, Aydin O, Mungan D, et al. Prevalence of asthma among the adult general population of five Middle Eastern countries: results of the SNAPSHOT program. BMC Pulm Med. 2018;18:68.
  • Global Initiative for Asthma (GINA). 2018 GINA report, global strategy for asthma management and prevention [cited 2019 April 8]. Available from: https://ginasthma.org/gina-reports/.
  • Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071–1076.
  • Rand C, Bilderback A, Schiller K, et al. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol. 2007;119:916–923.
  • Jónasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child. 2000;83:330–333.
  • Gonzalez F, de la Fuente-Cid R, Álvarez-Gil R, et al. [Factors associated with asthma control in primary care patients: the CHAS study]. Arch Bronconeumol. 2010;46:358–363.
  • Stanford RH, Shah MB, D’Souza AO, et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109:403–407.
  • Suissa S, Ernst P, Boivin J-F, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149:604–610.
  • Dalcin Pde T, Grutcki DM, Laporte PP, et al. Impact of short-term educational intervention on adherence to asthma treatment and on asthma control. J Bras Pneumol. 2011;37:19–27.
  • Darba J, Ramirez G, Sicras A, et al. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;10:2335–2345.
  • Papi A, Caramori G, Adcock IM, et al. Rescue treatment in asthma. More than as-needed bronchodilation. Chest. 2009;135:1628–1633.
  • Global Initiative for Asthma (GINA). GINA Implementation Pocket Guide; 2019 [cited 2019 Apr 10]. Available from: https://ginasthma.org/gina-implementation-guide/gina-implementation-pocket-guide-2019/.
  • O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017;50:1701103.
  • O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide–formoterol as needed in mild asthma. N Engl J Med. 2018;378:1865–1876.
  • Mabrouk AA, Abd El-Aziz AA, Agha MA, et al. Study of demographic and clinical characteristics of bronchial asthma patients in Mahalla Chest Hospital during the period from March 2013 to February 2014. Menoufia Med J. 2017;30:241–248.
  • Kawalec P, Malinowski K. Disease activity, quality of life and indirect costs of reduced productivity at work, generated by Polish patients with ankylosing spondylitis. Reumatologia. 2015;53:301–308.
  • Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices–budget impact analysis. Value Health. 2007;10:336–347.
  • The World Bank. Population data, Egypt, Arab Republic; 2017. [cited 2019 Apr 10]. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL?locations=EG.
  • Lakdawalla DN, Doshi JA, Garrison LP, et al. Defining elements of value in health care–a health economics approach: an ISPOR special task force report. Value Health. 2018;21:131–139.
  • Andersson F, Stahl E, Barnes PJ, et al. Adding formoterol to budesonide in moderate asthma—health economic results from the FACET study. Resp Med. 2001;95:505–512.
  • Truema PN, Drummond H. Developing guidance for budget impact analysis. Pharmacoeconomics. 2001;19:609–621.
  • Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies_practical applications and methodological shortcomings. PharmacoEconomics. 1997;12:121–129.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.